Genprex, Inc. (NASDAQ:GNPX) Sees Significant Decrease in Short Interest

Genprex, Inc. (NASDAQ:GNPX) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 633,100 shares, a decline of 44.0% from the February 13th total of 1,130,000 shares. Approximately 7.7% of the shares of the stock are short sold. Based on an average trading volume of 884,000 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Geode Capital Management LLC raised its position in Genprex, Inc. (NASDAQ:GNPX) by 368.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 76,045 shares of the company’s stock after buying an additional 59,798 shares during the period. Geode Capital Management LLC owned about 0.89% of Genprex worth $65,000 as of its most recent filing with the SEC. 14.05% of the stock is owned by hedge funds and other institutional investors.

Genprex Stock Up 0.9 %

Shares of GNPX traded up $0.00 on Friday, hitting $0.36. The company’s stock had a trading volume of 964,642 shares, compared to its average volume of 2,759,767. The company has a 50 day moving average price of $0.53 and a 200 day moving average price of $0.83. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $4.48.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.